FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013993096> ?p ?o ?g. }

• W2013993096 endingPage "1195" @default.
• W2013993096 startingPage "1186" @default.
• W2013993096 abstract "Despite advances in heart transplantation and mechanical circulatory support, mortality among transplant candidates remains high. Better ways are needed to ensure the survival of transplant candidates both inside and outside the hospital.In a prospective, multicenter clinical trial conducted at 24 centers in the United States, 280 transplant candidates (232 men, 48 women; median age, 55 years; range, 11-72 years) unresponsive to inotropic drugs, intra-aortic balloon counterpulsation, or both, were treated with the HeartMate Vented Electric Left Ventricular Assist System (VE LVAS). A cohort of 48 patients (40 men, 8 women; median age, 50 years; range, 21-67 years) not supported with an LVAS served as a historical control group. Outcomes were measured in terms of laboratory data (hemodynamic, hematologic, and biochemical), adverse events, New York Heart Association functional class, and survival.The VE LVAS-treated and non-VE LVAS-treated (control) groups were similar in terms of age, sex, and distribution of patients by diagnosis (ischemic cardiomyopathy, idiopathic cardiomyopathy, and subacute myocardial infarction). VE LVAS support lasted an average of 112 days (range, < 1-691 days), with 54 patients supported for > 180 days. Mean VE LVAS flow (expressed as pump index) throughout support was 2.8 L x min(-1) x m(-2). Median total bilirubin values decreased from 1.2 mg/dL at baseline to 0.7 mg/dL (P =.0001); median creatinine values decreased from 1.5 mg/dL at baseline to 1.1 mg/dL (P =.0001). VE LVAS-related adverse events included bleeding in 31 patients (11%), infection in 113 (40%), neurologic dysfunction in 14 (5%), and thromboembolic events in 17 (6%). A total of 160 (58%) patients were enrolled in a hospital release program. Twenty-nine percent of the VE LVAS-treated patients (82/280) died before receiving a transplant, compared with 67% of controls (32/48) (P <.001). Conversely, 71% of the VE LVAS-treated patients (198/280) survived: 67% (188/280) ultimately received a heart transplant, and 4% (10/280) had the device removed electively. One-year post-transplant survival of VE LVAS-treated patients was significantly better than that of controls (84% [158/188] vs 63% [10/16]; log rank analysis P =.0197).The HeartMate VE LVAS provides adequate hemodynamic support, has an acceptably low incidence of adverse effects, and improves survival in heart transplant candidates both inside and outside the hospital. The studies of the HeartMate LVAS (both pneumatic and electric) for Food and Drug Administration approval are the only studies with a valid control group to show a survival benefit for cardiac transplantation." @default.
• W2013993096 created "2016-06-24" @default.
• W2013993096 creator A5011854639 @default.
• W2013993096 creator A5011932512 @default.
• W2013993096 creator A5044332454 @default.
• W2013993096 creator A5055613863 @default.
• W2013993096 creator A5061706688 @default.
• W2013993096 creator A5062496285 @default.
• W2013993096 creator A5079801612 @default.
• W2013993096 creator A5087980707 @default.
• W2013993096 date "2001-12-01" @default.
• W2013993096 modified "2023-10-10" @default.
• W2013993096 title "Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation" @default.
• W2013993096 cites W1539005693 @default.
• W2013993096 cites W185490317 @default.
• W2013993096 cites W1980746278 @default.
• W2013993096 cites W1994892653 @default.
• W2013993096 cites W1997941863 @default.
• W2013993096 cites W1999279648 @default.
• W2013993096 cites W1999487197 @default.
• W2013993096 cites W2003733359 @default.
• W2013993096 cites W2028619830 @default.
• W2013993096 cites W2030553750 @default.
• W2013993096 cites W2036444290 @default.
• W2013993096 cites W2056804173 @default.
• W2013993096 cites W2091349813 @default.
• W2013993096 cites W2093298137 @default.
• W2013993096 cites W2101649440 @default.
• W2013993096 cites W2146897448 @default.
• W2013993096 cites W2154260320 @default.
• W2013993096 cites W2333535844 @default.
• W2013993096 cites W4245244523 @default.
• W2013993096 doi "https://doi.org/10.1067/mtc.2001.118274" @default.
• W2013993096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11726895" @default.
• W2013993096 hasPublicationYear "2001" @default.
• W2013993096 type Work @default.
• W2013993096 sameAs 2013993096 @default.
• W2013993096 citedByCount "503" @default.
• W2013993096 countsByYear W20139930962012 @default.
• W2013993096 countsByYear W20139930962013 @default.
• W2013993096 countsByYear W20139930962014 @default.
• W2013993096 countsByYear W20139930962015 @default.
• W2013993096 countsByYear W20139930962016 @default.
• W2013993096 countsByYear W20139930962017 @default.
• W2013993096 countsByYear W20139930962018 @default.
• W2013993096 countsByYear W20139930962019 @default.
• W2013993096 countsByYear W20139930962020 @default.
• W2013993096 countsByYear W20139930962021 @default.
• W2013993096 countsByYear W20139930962022 @default.
• W2013993096 countsByYear W20139930962023 @default.
• W2013993096 crossrefType "journal-article" @default.
• W2013993096 hasAuthorship W2013993096A5011854639 @default.
• W2013993096 hasAuthorship W2013993096A5011932512 @default.
• W2013993096 hasAuthorship W2013993096A5044332454 @default.
• W2013993096 hasAuthorship W2013993096A5055613863 @default.
• W2013993096 hasAuthorship W2013993096A5061706688 @default.
• W2013993096 hasAuthorship W2013993096A5062496285 @default.
• W2013993096 hasAuthorship W2013993096A5079801612 @default.
• W2013993096 hasAuthorship W2013993096A5087980707 @default.
• W2013993096 hasBestOaLocation W20139930961 @default.
• W2013993096 hasConcept C126322002 @default.
• W2013993096 hasConcept C141071460 @default.
• W2013993096 hasConcept C155710745 @default.
• W2013993096 hasConcept C164705383 @default.
• W2013993096 hasConcept C197934379 @default.
• W2013993096 hasConcept C2775932942 @default.
• W2013993096 hasConcept C2776383484 @default.
• W2013993096 hasConcept C2778198053 @default.
• W2013993096 hasConcept C2778774980 @default.
• W2013993096 hasConcept C2778797674 @default.
• W2013993096 hasConcept C2778849806 @default.
• W2013993096 hasConcept C2780306776 @default.
• W2013993096 hasConcept C2911091166 @default.
• W2013993096 hasConcept C500558357 @default.
• W2013993096 hasConcept C71924100 @default.
• W2013993096 hasConcept C78085059 @default.
• W2013993096 hasConceptScore W2013993096C126322002 @default.
• W2013993096 hasConceptScore W2013993096C141071460 @default.
• W2013993096 hasConceptScore W2013993096C155710745 @default.
• W2013993096 hasConceptScore W2013993096C164705383 @default.
• W2013993096 hasConceptScore W2013993096C197934379 @default.
• W2013993096 hasConceptScore W2013993096C2775932942 @default.
• W2013993096 hasConceptScore W2013993096C2776383484 @default.
• W2013993096 hasConceptScore W2013993096C2778198053 @default.
• W2013993096 hasConceptScore W2013993096C2778774980 @default.
• W2013993096 hasConceptScore W2013993096C2778797674 @default.
• W2013993096 hasConceptScore W2013993096C2778849806 @default.
• W2013993096 hasConceptScore W2013993096C2780306776 @default.
• W2013993096 hasConceptScore W2013993096C2911091166 @default.
• W2013993096 hasConceptScore W2013993096C500558357 @default.
• W2013993096 hasConceptScore W2013993096C71924100 @default.
• W2013993096 hasConceptScore W2013993096C78085059 @default.
• W2013993096 hasIssue "6" @default.
• W2013993096 hasLocation W20139930961 @default.
• W2013993096 hasLocation W20139930962 @default.
• W2013993096 hasOpenAccess W2013993096 @default.
• W2013993096 hasPrimaryLocation W20139930961 @default.
• W2013993096 hasRelatedWork W1606426552 @default.

• next